drugset
drugset / Trial / NCT05993299

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

NCT05993299 ↗

Phase 2 Active not recruiting 7 enrolled USWM, LLC (dba US WorldMeds)
NaSingle-groupOpen-labelTreatment

Summary

This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors. This trial is a sub study of the Master study NCT03967223.

Timeline

Start
2019-12-31
Primary completion
2022-10-12
Completion
2026-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Letetresgene autoleucel Cell therapy — —
Background Cyclophosphamide Other / unclassified — —
Background Fludarabine Small molecule — —

Indications

neoplasm